Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

St Clair, 2004, Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial, Arthritis Rheum, 50, 3432, 10.1002/art.20568 Breedveld, 2006, Arthritis Rheum, 54, 26, 10.1002/art.21519 Van der Heijde, 2006, Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial, Arthritis Rheum, 54, 1063, 10.1002/art.21655 1993, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, Neurology, 43, 655, 10.1212/WNL.43.4.655 Jacobs, 1996, Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, Ann Neurol, 39, 285, 10.1002/ana.410390304 Johnson, 1995, Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial, Neurology, 45, 1268, 10.1212/WNL.45.7.1268 1998, Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis, Lancet, 352, 1498, 10.1016/S0140-6736(98)03334-0 Yednock, 1992, Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin, Nature, 356, 63, 10.1038/356063a0 Polman, 2006, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, 354, 889, 10.1056/NEJMoa044397 McDonald, 2001, Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis, Ann Neurol, 50, 121, 10.1002/ana.1032 Kurtzke, 1983, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, 33, 1444, 10.1212/WNL.33.11.1444 Munschauer, 2008, Natalizumab significantly increases the cumulative probability of sustained improvement in physical disability, Mult Scler, 14, S167